Non-inferiority Evaluation of Multicenter, Randomized, Single-blind, Parallel-controlled Clinical Trials on the Safety and Efficacy of Full-suture Anchors for Rotator Cuff Injury and/or Shoulder Instability Surgery

Inclusion Criteria: 1. The age of the patients ranged from 18 to 75 years (including 18 and 75 years), with no gender limitation 2. Patients with rotator cuff injury and/or instability of the shoulder joint are eligible for surgical indications of suture anchor 3. Subjects were willing and able to sign informed consent Exclusion Criteria: 1. Patients with severe osteoporosis； 2. A variety of conditions, such as previous infection, suspected infection, current infection, that may or may lead to insufficient implant support or impaired rehabilitation； 3. Those with severe allergic constitution (e.g. severe allergic purpura, asthma, rhinitis, shock, etc.)； 4. Patients with abnormal liver and kidney function \[SGPT (ALT) or SGOT (AST) or creatinine (CR)\] were 1.5 times higher than the upper limit of normal value; patients with coagulation dysfunction (such as prothrombin time (PT) prolonged or shortened \> 3 s, activated partial thromboplastin time (aPTT) prolonged or shortened \> 10 s, platelet count (PLT) \< 50 \*109/L)； 5. Those with severe cardiopulmonary disease and uncontrolled epilepsy within half a year are limited to participate in the study； 6. Cervical spinal cord disease, brachial plexus nerve injury, poor compliance, psychosis, mental disorders, difficult to cooperate with； 7. Pregnancy test positive, pregnant or lactating women, recent family planning; during the trial can not take feasible contraceptive measure； 8. Surgical site peripheral nerve injury； 9. Subjects who had participated in clinical studies of other drugs, biological agents or medical devices before enrollment did not reach the primary endpoint 10. High blood pressure control is still not suitable for surgery； 11. Malignant Tumor Patients； 12. Researchers believe that there are other circumstances that are not suitable for this clinical trial.